MannKind shares rose nearly 20% on Aug. 8, one day after the company highlighted its earnings results for the second quarter of 2022. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, delivered revenue worth $49.6 million in the second quarter of 2023, up 157% from the same quarter a year…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
